Search results for Lanadelumab
Lanadelumab Biosimilar – Anti-KLKB1 mAb – Research Grade, ProteoGenix, PX-TA1423
Description of Lanadelumab Biosimilar - Anti-KLKB1 mAb - Research Grade General information on Anti-KLKB1[Homo sapiens] (Lanadelumab) Monoclonal Antibody Lanadelumab is a human IgG1 monoclonal antibody taht targets KLKB1. It is used to treat Hereditary angioedema.
Host
Reactivity
Applications
Conjugation
Lanadelumab, Abbexa, abx831380
Lanadelumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting KLKB1, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Lanadelumab, also known as DX-2930, is a human IgG1 monoclonal antibody designed for subcutaneous self-injection. It is a fully human immunoglobulin, k-light-chain made in recombinant Chinese Hamster Ovary cells. The FDA and EU granted the designation of priority review, breakthrough therapy and orphan drug for rare diseases based on the results of the reported clinical trials. Lanadelumab was developed by Shire and FDA approved on August 28, 2018. 5.
Host
Human
Reactivity
Human
Applications
ELISA, WB
Conjugation
Unconjugated
Lanadelumab Biosimilar - Research Grade, ichor.bio, ICH5302
Detects human KLKB1
Host
CHO Cells
Reactivity
Human
Applications
Conjugation
Please provide the required information below so that we can quickly source your products.